Source: Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Unidade: FCFRP
Subjects: FÁRMACOS, DIABETES MELLITUS, CUSTO ECONÔMICO, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAZARIM, Maurílio de Souza et al. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, v. 11, p. S859-S865, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.dsx.2017.07.006. Acesso em: 18 out. 2024.APA
Cazarim, M. de S., Cazarim, E. L. C. da C., Baldoni, A. de O., Santos, T. B. E. dos, Souza, P. G. de, Silva, I. de A., et al. (2017). Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 11, S859-S865. doi:10.1016/j.dsx.2017.07.006NLM
Cazarim M de S, Cazarim ELC da C, Baldoni A de O, Santos TBE dos, Souza PG de, Silva I de A, Rodrigues RNR, Maia ACFC, Pereira LRL, Sanches C. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus [Internet]. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017 ; 11 S859-S865.[citado 2024 out. 18 ] Available from: https://doi.org/10.1016/j.dsx.2017.07.006Vancouver
Cazarim M de S, Cazarim ELC da C, Baldoni A de O, Santos TBE dos, Souza PG de, Silva I de A, Rodrigues RNR, Maia ACFC, Pereira LRL, Sanches C. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus [Internet]. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017 ; 11 S859-S865.[citado 2024 out. 18 ] Available from: https://doi.org/10.1016/j.dsx.2017.07.006